The discovery and development of gefapixant

Gefapixant is the approved generic name for a compound also known as MK-7264, and prior to that AF-219 and RO-4926219. It is the first-in-class clinically developed antagonist for the P2X3 subtype of trimeric ionotropic purinergic receptors, a family of ATP-gated excitatory ion channels, showing nan...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Autonomic neuroscience 2021-11, Vol.235, p.102859-102859, Article 102859
Hauptverfasser:	Ford, Anthony P., Dillon, Michael P., Kitt, Michael M., Gever, Joel R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine triphosphate ATP Cough Gefapixant P2X3 receptors Pain Purinergic signaling Respiratory symptoms Taste
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!